

# **TYRA BIOSCIENCES, INC.**

Reported by  
**HARRIS TODD**

## **FORM 4**

(Statement of Changes in Beneficial Ownership)

Filed 10/17/24 for the Period Ending 10/15/24

Address	2656 STATE STREET CARLSBAD, CA, 92008
Telephone	(619) 728-4760
CIK	0001863127
Symbol	TYRA
Fiscal Year	12/31

# FORM 4

OMB APPROVAL  
OMB Number: 3235-0287  
Estimated average burden  
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or  
Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person *</b>  <b>Harris Todd</b>  <small>(Last) (First) (Middle)</small>  <b>C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET</b>  <small>(Street)</small>  <b>CARLSBAD, CA 92008</b>  <small>(City) (State) (Zip)</small>	<b>2. Issuer Name and Ticker or Trading Symbol</b>  <b>Tyra Biosciences, Inc. [ TYRA ]</b>  <b>3. Date of Earliest Transaction (MM/DD/YYYY)</b>  <p align="center"><b>10/15/2024</b></p>	<b>5. Relationship of Reporting Person(s) to Issuer</b> (Check all applicable)  <input type="checkbox"/> Director <span style="float:right">_____ 10% Owner</span> <input checked="" type="checkbox"/> Officer (give title below) <span style="float:right">_____ Other (specify below)</span> <p align="center"><b>President and CEO</b></p>
<b>4. If Amendment, Date Original Filed (MM/DD/YYYY)</b>		<b>6. Individual or Joint/Group Filing (Check Applicable Line)</b>  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/15/2024		S <sup>(1)</sup>		10,035	D	\$24.3119 <sup>(2)</sup>	1,467,338	D	
Common Stock	10/16/2024		S <sup>(1)</sup>		4,900	D	\$25.2155 <sup>(3)</sup>	1,462,438	D	
Common Stock	10/16/2024		S <sup>(1)</sup>		24,475	D	\$26.2334 <sup>(4)</sup>	1,437,963	D	
Common Stock	10/16/2024		S <sup>(1)</sup>		3,922	D	\$26.9789 <sup>(5)</sup>	1,434,041	D	
Common Stock	10/17/2024		S <sup>(1)</sup>		15,194	D	\$25.839 <sup>(6)</sup>	1,418,847	D	
Common Stock	10/17/2024		S <sup>(1)</sup>		200	D	\$26.37	1,418,647	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date				

**Explanation of Responses:**

- (1) The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2022.
- (2) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$24.00 to \$24.8667. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$24.72 to \$25.59. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (4) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$25.78 to \$26.78. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (5) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$26.79 to \$27.08. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (6) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between \$25.30 to \$26.16. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
<b>Harris Todd</b> C/O TYRA BIOSCIENCES, INC. 2656 STATE STREET CARLSBAD, CA 92008	X		<b>President and CEO</b>	

**Signatures**/s/ Ali D. Fawaz, Attorney-in-Fact10/17/2024

\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.